Virtual Presentation

Options for High Risk AML and MDS

Source: Navigating the Therapeutic Pathways for AML and MDS

Options for High Risk AML and MDS

Faculty:

Daniel Weisdorf, MD

CREDIT INFORMATION

Release Date: February 12, 2010

Expiration Date: February 11, 2011

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Understand the role of risk stratification in treatment decision making in high-risk AML and MDS
Explain the rationale for HLA typing at diagnosis for patients with high-risk AML and MDS
Compare the outcomes of matched related donor and matched unrelated donor transplants in patients with high-risk AML
Describe the influence of hematopoietic cell transplantation timing on outcomes in patients with MDS and high-risk AML

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.